journal article·2023-01-11

Recombinant High-Density Lipoprotein Boosts the Therapeutic Efficacy of Mild Hypothermia in Traumatic Brain Injury

Jialin Huang, Han Zhu, Ping Yu, Yuxiao Ma, Jingru Gong, Yuli Fu, Huahua Song, Meng Huang, Jing Luo, Jiyao Jiang, Xiaoling Gao, Junfeng Feng, Gan Jiang

Publisher page

Abstract

Traumatic brain injury (TBI) leads to neuropsychiatric symptoms and increased risk of neurodegenerative disorders. Mild hypothermia is commonly used in patients suffering from severe TBI. However, its effect for long-term protection is limited, mostly because of its insufficient anti-inflammatory and neuroprotective efficacy and restricted treatment duration. Recombinant high-density lipoprotein (rHDL), which possesses anti-inflammatory and antioxidant activity and blood-brain barrier (BBB) permeability, was expected to potentially strengthen the therapeutic effect of mild hypothermia in TBI treatment. To test this hypothesis and optimize the regimen for combination therapy, the efficacy of mild hypothermia plus concurrent or sequential rHDL on oxidative stress, inflammatory reaction, and cell survival in the damaged brain cells was evaluated. It was found that the effect of combining mild hypothermia with concurrent rHDL was modest, as mild hypothermia inhibited the cellular uptake and lesion-site-targeting delivery of rHDL. In contrast, the combination of mild hypothermia with sequential rHDL more powerfully improved the anti-inflammatory and antioxidant activities, promoted nerve cell survival and BBB restoration, and ameliorated neurologic changes, which thus remarkably restored the spatial learning and memory ability of TBI mice. Collectively, these findings suggest that rHDL may serve as a novel nanomedicine for adjunctive therapy of TBI and highlight the importance of timing of combination therapy for optimal treatment outcome.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Traumatic Brain Injury and Neurovascular Disturbances · Thermal Regulation in Medicine · Metabolomics and Mass Spectrometry Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Brain Injury Center, Renji Hospital, Shanghai Institute of Head Trauma, School of Medicine, Shanghai Jiao Tong University, No. 160 Pujian Road, Shanghai 200127, China

Department of Pharmacy, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, No. 2800 Gongwei Road, Shanghai 201399, China

Department of Pharmacy, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197 Rui Jin Er Road, Shanghai 200025, China

Department of Pharmacology and Chemical Biology, Shanghai Universities Collaborative Innovation Center for Translational Medicine, Shanghai Jiao Tong University School of Medicine, 280 South Chongqing Road, Shanghai 200025, China

Funding

Shanghai Municipal Health and Family Planning Commission · Shanghai Science and Technology Development Foundation · Science and Technology Commission of Shanghai Municipality · National Natural Science Foundation of China · Shanghai talent development funding · Innovative research team of high-level local universities in Shanghai

References (35)

Show source-provided references
1. 10.1016/S1474-4422(17)30371-X10.1016/S1474-4422(17)30371-X ↗
2. 10.3389/fncel.2019.0052810.3389/fncel.2019.00528 ↗
3. 10.1016/j.eclinm.2021.10073210.1016/j.eclinm.2021.100732 ↗
4. 10.1146/annurev-bioeng-061008-12490810.1146/annurev-bioeng-061008-124908 ↗
5. 10.1001/jama.2018.1707510.1001/jama.2018.17075 ↗
6. 10.2174/092986732666619050612483610.2174/0929867326666190506124836 ↗
7. 10.1016/S1474-4422(06)70630-510.1016/S1474-4422(06)70630-5 ↗
8. 10.1056/NEJMoa06751410.1056/NEJMoa067514 ↗
9. 10.2217/nnm-2019-036710.2217/nnm-2019-0367 ↗
10. 10.3389/fneng.2013.0000710.3389/fneng.2013.00007 ↗
11. 10.3389/fimmu.2020.0202110.3389/fimmu.2020.02021 ↗
12. 10.3390/ijms2201010610.3390/ijms22010106 ↗
13. 10.1161/CIRCRESAHA.111.30058110.1161/CIRCRESAHA.111.300581 ↗
14. 10.1097/MOL.000000000000060410.1097/MOL.0000000000000604 ↗
15. 10.1021/acsnano.8b0684210.1021/acsnano.8b06842 ↗
16. 10.1186/s13054-020-02860-310.1186/s13054-020-02860-3 ↗
17. 10.1002/dmrr.105710.1002/dmrr.1057 ↗
18. 10.1084/jem.2020205910.1084/jem.20202059 ↗
19. 10.1161/ATVBAHA.116.30702310.1161/ATVBAHA.116.307023 ↗
20. 10.1039/C9BM01395D10.1039/C9BM01395D ↗
21. 10.1021/acsami.7b1852510.1021/acsami.7b18525 ↗
22. 10.1021/nn405821510.1021/nn4058215 ↗
23. 10.1021/acsnano.5b0752210.1021/acsnano.5b07522 ↗
24. 10.1097/MOL.0b013e32833bcdc110.1097/MOL.0b013e32833bcdc1 ↗
25. 10.3390/ijms2018458210.3390/ijms20184582 ↗
26. 10.1038/sj.bjp.070640010.1038/sj.bjp.0706400 ↗
27. 10.1016/j.cell.2020.02.01310.1016/j.cell.2020.02.013 ↗
28. 10.1097/00005373-200202000-0002110.1097/00005373-200202000-00021 ↗
29. 10.1038/s41598-020-73227-510.1038/s41598-020-73227-5 ↗
30. 10.1016/j.expneurol.2015.05.02410.1016/j.expneurol.2015.05.024 ↗
31. 10.1021/acsnano.9b0918610.1021/acsnano.9b09186 ↗
32. 10.1021/acsnano.7b0342610.1021/acsnano.7b03426 ↗
33. 10.1016/j.apsb.2020.11.02310.1016/j.apsb.2020.11.023 ↗
34. 10.1038/nrneurol.2010.7410.1038/nrneurol.2010.74 ↗
35. 10.1016/j.tem.2013.10.00310.1016/j.tem.2013.10.003 ↗